REG - e-Therapeutics plc - Total Voting Rights

E-TherapeuticsAnnouncement

28/04/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230428:nRSb9423Xa&default-theme=true

RNS Number : 9423X  e-Therapeutics plc  28 April 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Total Voting Rights

 

 

London, UK, 28 April 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that in accordance with the
Financial Conduct Authority's Disclosure and Transparency Rules, the Company
has 582,659,332 ordinary shares of 0.1 pence each in issue, none of which are
held in treasury. Therefore, the total number of voting rights in the Company
is 582,659,332.

 

The above figure of 582,659,332 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company.

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Laura Roca-Alonso, COO                                                             www.etherapeutics.co.uk

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary HepNetÔ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmicÔ, ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNetÔ.  The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmicÔ
constructs have demonstrated compelling in vivo performance in terms of
depth of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class pre-clinical RNAi
candidates across a several high unmet medical needs in cardiometabolic
indications and targeting promising hepatocyte-expressed with effects in other
disease areas. ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its computational network
biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRMZGZDKRLGFZM